Pfizer and BioNTech COVID-19 vaccine candidate shows 90% effectiveness in third phase trials

Pfizer BioNTech

In the search for COVID-19 vaccine, the world has got a good news as the vaccine candidate developed by Pfizer and BioNTech shows effectiveness in 90% of participants in the 3rd phase of the clinical trials as announced by the company on Monday.

The report published by the company notes that this report is only based on the data analyzed by an external, independent committee assigned to check the results of the trial, and this data reflects the early results from the trial only and not the final verified results.

The company says that the vaccine candidate developed by Pfizer and BioNtTech is an mRNA-based vaccine that is a newer technology most of the company pursued for COVID-19 in part because it offers some advantages in the pace of development and potential efficacy.

The results from the test were based on an equable case total of 94 confirmed COVID-19 cases among study participants – passing the minimum threshold agreed to by the companies and the FDA of 62 confirmed cases for a proper, scientifically rigorous assessment.

The report notes that the phase 3 trial conducted by the company included 43,358 participants and the company notes that “no serious safety concerns have been observed” thus far in addition to the positive prevention rate.

Based on the early data of the trial, individuals who received the vaccine are protected at 28 days after first dose and the vaccine uses a two-dose process for complete effectiveness.

The current vaccine candidate still requires additional safety testing and continued studies to be conducted with the companies estimating that two full months of safety data (which is what the FDA requires for Emergency Use Authorization) will be available in the third week of this month.

The company notes that the participants will also be monitored for two full years after they receive their second and final dose in order to test for long-term effects.

Pfizer notes that the company can produce up to 50 million doses of its vaccine by the end of this year, and as many as 1.3 billion does through 2021.

Further data from this trial will undergo strict review by other researchers and scientific publications, but this news is promising and a positive news in the massive research for the development of COVID-19 vaccine around the world.

Leave a Reply